Suppliers and packagers for MICAFUNGIN

MICAFUNGIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ph Health	MICAFUNGIN	micafungin sodium	POWDER;INTRAVENOUS	212156	NDA	Par Health USA, LLC	42023-229-10	10 VIAL, SINGLE-DOSE in 1 CARTON (42023-229-10) / 10 mL in 1 VIAL, SINGLE-DOSE	2021-08-01
Ph Health	MICAFUNGIN	micafungin sodium	POWDER;INTRAVENOUS	212156	NDA	Par Health USA, LLC	42023-230-10	10 VIAL, SINGLE-DOSE in 1 CARTON (42023-230-10) / 10 mL in 1 VIAL, SINGLE-DOSE	2021-08-01

Micafungin Pharmaceutical Drug: Supply Chain Analysis

Last updated: February 19, 2026

Micafungin sodium, an echinocandin antifungal, is a critical therapeutic for invasive fungal infections. Its supply chain is influenced by the proprietary synthesis processes of its originator, Astellas Pharma, and the increasing market penetration by generic manufacturers. Key suppliers for micafungin encompass raw material providers, intermediate chemical manufacturers, and finished dosage form producers. Regulatory compliance, patent landscape, and manufacturing capacity are principal drivers of supply chain stability and cost.

Who Are the Key Suppliers for Micafungin?

The supply chain for micafungin sodium involves multiple tiers of specialized chemical and pharmaceutical manufacturers. Identification of specific raw material suppliers is often proprietary to the active pharmaceutical ingredient (API) manufacturers, but the general categories of suppliers and their roles are established.

Raw Material and Intermediate Suppliers

The synthesis of micafungin sodium is a complex, multi-step process. This requires a secure supply of specialized chemical building blocks and advanced intermediates.

• Amino Acid Derivatives: The core structure of micafungin includes modified amino acids. Companies specializing in custom peptide synthesis and chiral chemistry are essential for providing these high-purity components.
• Lipid Precursors: The lipopeptide nature of micafungin necessitates suppliers of specific fatty acid derivatives and related lipid components. These are often derived from fermentation or specialized chemical synthesis.
• Coupling Reagents and Catalysts: The peptide bond formation and subsequent modifications require highly specific reagents and catalysts. Suppliers of fine chemicals with expertise in organic synthesis are crucial.
• Solvents and Reagents: High-purity solvents and a range of other reagents are required for synthesis, purification, and isolation steps. Pharmaceutical-grade suppliers are necessary to meet regulatory standards.

Companies operating in this segment often do not publicly disclose their direct involvement in specific drug supply chains due to confidentiality agreements. However, the market for these specialized fine chemicals is competitive, with a focus on quality, consistency, and adherence to Good Manufacturing Practices (GMP).

Active Pharmaceutical Ingredient (API) Manufacturers

The production of the micafungin sodium API is a highly specialized process. Astellas Pharma, the originator, likely maintains significant in-house API manufacturing capacity or utilizes highly vetted Contract Manufacturing Organizations (CMOs).

• Astellas Pharma: As the innovator, Astellas Pharma is the primary API producer for its branded product, Mycamine. Their manufacturing sites in Japan and potentially other regions adhere to stringent quality controls.
• Generic API Manufacturers: With the patent expiry of micafungin, several generic pharmaceutical companies have entered or are planning to enter the market. These companies either establish their own API manufacturing capabilities or contract with specialized API CMOs.
  • Major API CMOs: Global API manufacturers with expertise in complex synthesis, fermentation, and sterile processing are potential partners for generic companies. These often include companies in India, China, and Europe. Examples of companies with broad capabilities include Lonza, Siegfried, and several large Indian API manufacturers. Specific micafungin API suppliers for generic markets are often identified through regulatory filings and patent litigation documents.

Finished Dosage Form (FDF) Manufacturers

The final step in the supply chain is the formulation of micafungin sodium into its injectable dosage form. This requires sterile manufacturing facilities capable of handling lyophilized powders.

• Astellas Pharma: Produces the branded Mycamine product.
• Generic FDF Manufacturers: Companies seeking to market generic micafungin vials will either have their own sterile fill-and-finish capabilities or will outsource this to specialized FDF CMOs.
  • Sterile Injectable CMOs: These facilities must comply with strict GMP regulations for sterile product manufacturing, including aseptic processing or terminal sterilization where applicable. Companies offering lyophilization services are particularly relevant. The list of qualified CMOs capable of sterile injectable manufacturing is finite and includes companies with established track records in complex drug products.

What is the Patent Landscape for Micafungin?

The patent landscape for micafungin sodium is critical for understanding market dynamics and potential supply chain disruptions. The original patents granted to Astellas Pharma have been central to its market exclusivity.

Core Composition of Matter Patents

• US Patent 5,352,787: This patent, titled "Echinocandin derivatives," claims novel echinocandin compounds, including micafungin. It was filed on October 2, 1992, and issued on October 3, 1994. This patent provided the foundational intellectual property for micafungin. (Source: USPTO)
• EP 0573814 B1: The European counterpart to the US composition of matter patent. (Source: EPO)

The expiration of these core patents is a prerequisite for generic market entry.

Formulation and Method of Use Patents

Beyond the composition of matter, Astellas has also secured patents covering specific formulations, manufacturing processes, and methods of treating particular fungal infections with micafungin. These "secondary patents" can extend market exclusivity or present challenges for generic competitors.

• Manufacturing Process Patents: Patents covering specific synthetic routes or purification techniques for micafungin API can create barriers. For example, patents related to specific chiral separation methods or improved crystallization processes.
• Formulation Patents: Patents for specific lyophilized formulations, excipients used, or packaging configurations designed to improve stability or ease of administration.
• Method of Use Patents: Patents claiming the use of micafungin for specific indications or in combination therapies.

Generic companies must carefully navigate this complex patent landscape to avoid infringement. This often involves designing around existing patents or challenging their validity through litigation.

Patent Expirations and Generic Entry

• Key Patent Expirations: The expiration dates of primary patents directly influence when generic versions can be introduced. The US composition of matter patent (5,352,787) has long expired. However, market exclusivity for branded drugs is also influenced by regulatory exclusivities (e.g., Hatch-Waxman Act exclusivities in the US) and the lifespan of secondary patents.
• Paragraph IV Filings: In the US, generic manufacturers can challenge patents by filing an Abbreviated New Drug Application (ANDA) and asserting that the patents are invalid, unenforceable, or will not be infringed by the generic product. This often leads to patent litigation.
• Global Patent Strategies: Astellas has pursued patent protection in major markets globally, with varying expiry dates depending on national patent laws and extensions (e.g., Patent Term Extensions).

The timing of generic entry has been impacted by ongoing litigation and patent challenges by companies seeking to launch their versions of micafungin.

What Are the Regulatory Considerations for Micafungin Suppliers?

Regulatory compliance is paramount for all suppliers in the micafungin supply chain. Failure to meet these standards can result in product recalls, import alerts, and significant financial penalties.

Good Manufacturing Practices (GMP)

All facilities involved in the manufacturing of micafungin API and its finished dosage form must adhere to stringent GMP regulations.

• FDA (U.S. Food and Drug Administration): Requires compliance with 21 CFR Parts 210 and 211 for finished pharmaceuticals and 21 CFR Part 211 for APIs. Inspections are conducted regularly.
• EMA (European Medicines Agency): Mandates compliance with EudraLex Volume 4, which outlines GMP guidelines for medicinal products.
• Other Regulatory Bodies: Suppliers must also comply with the GMP requirements of other national regulatory agencies where the drug will be marketed (e.g., PMDA in Japan, Health Canada).

Key GMP aspects include:

• Quality Management Systems: Robust systems for change control, deviation management, CAPA (Corrective and Preventive Actions), and batch record review.
• Facility and Equipment Qualification: Validation of all manufacturing equipment and facilities to ensure consistent performance.
• Process Validation: Demonstrating that manufacturing processes consistently produce a product meeting its predetermined specifications and quality attributes.
• Analytical Method Validation: Validation of all testing methods used for raw materials, in-process controls, and final product release.
• Traceability and Documentation: Comprehensive record-keeping for all manufacturing and quality control activities.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs)

API manufacturers typically submit DMFs to regulatory agencies (e.g., FDA) or apply for CEPs (from EDQM in Europe).

• DMFs: Contain confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory agencies to review the API without the API manufacturer disclosing proprietary information directly to the drug product manufacturer.
• CEPs: A certificate issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that an API complies with the requirements of the European Pharmacopoeia.

These documents are critical for FDF manufacturers to gain regulatory approval for their drug products.

Impurity Profiling and Control

Controlling impurities, including process-related impurities, degradation products, and residual solvents, is a critical regulatory requirement.

• ICH Guidelines: International Council for Harmonisation (ICH) guidelines (e.g., ICH Q3A/B/C/D) provide frameworks for identifying, qualifying, and controlling impurities.
• Genotoxic Impurities: Special attention is given to potentially genotoxic impurities, which require extremely low acceptable limits.

Suppliers must have sophisticated analytical capabilities to identify and quantify all relevant impurities and demonstrate their control.

Supply Chain Security and Traceability

Regulations increasingly focus on ensuring the security and traceability of pharmaceutical supply chains to prevent counterfeiting and diversion.

• Serialization and Track-and-Trace: Requirements for unique product identifiers on drug packaging to enable tracking from manufacturer to dispenser.
• Audits and Supplier Qualification: Drug product manufacturers conduct rigorous audits of their API and FDF suppliers to ensure ongoing compliance and quality.

How Does Manufacturing Capacity Influence Micafungin Supply?

The availability of adequate manufacturing capacity is a primary determinant of micafungin supply, impacting both cost and reliability.

Specialized Synthesis and Sterile Manufacturing

The production of micafungin involves complex chemical synthesis requiring specialized equipment and highly trained personnel. Furthermore, the conversion of the API into an injectable lyophilized product demands sterile manufacturing facilities, which are capital-intensive and have limited global capacity.

• API Synthesis Capacity: Companies capable of multi-step organic synthesis, particularly those with experience in peptide chemistry and fermentation-derived molecules, are essential. Expanding this capacity can take years and significant investment.
• Sterile Fill-and-Finish Capacity: The lyophilization process is energy-intensive and requires specialized freeze-dryers. The number of facilities with qualified aseptic processing and lyophilization capabilities for parenteral drugs is limited.

Impact of Generic Entry on Capacity

The entry of multiple generic manufacturers increases demand for both API and FDF manufacturing slots.

• Increased Demand for API: Each generic entrant requires a reliable source of micafungin API. This can strain the capacity of existing API manufacturers or incentivize new players to enter the market.
• Competition for FDF Capacity: Generic companies often rely on CMOs for sterile fill-and-finish. Increased demand can lead to higher contract manufacturing costs and longer lead times.
• Dual Sourcing Strategies: To mitigate supply chain risks, both branded and generic manufacturers often employ dual sourcing strategies. This requires qualifying multiple suppliers for critical raw materials, intermediates, and APIs. However, for highly specialized products like micafungin, the number of qualified suppliers may be restricted.

Geographic Concentration of Manufacturing

The pharmaceutical manufacturing industry has seen a global shift, with significant API and FDF production concentrated in certain regions, notably India and China. While this can lead to cost efficiencies, it also introduces geopolitical and logistical risks.

• Geopolitical Risks: Supply chain disruptions due to trade disputes, political instability, or natural disasters in key manufacturing regions can impact micafungin availability.
• Logistical Challenges: Long supply chains increase transit times and the potential for damage or spoilage during transportation.

Lead Times and Inventory Management

The extended lead times associated with complex pharmaceutical manufacturing mean that suppliers must manage inventory effectively to meet demand.

• Long Manufacturing Cycles: The multi-step synthesis of micafungin API can take several months.
• Inventory Holding Costs: Holding significant raw material or API inventory incurs substantial costs, requiring careful forecasting and risk assessment.

Key Takeaways

• The micafungin supply chain is multi-tiered, involving specialized suppliers of raw materials, intermediates, API, and finished dosage forms.
• Astellas Pharma holds foundational patents, but patent expirations have opened the door for generic competition, leading to increased demand and supply chain complexity.
• Regulatory compliance, particularly GMP and impurity control, is critical for all suppliers.
• Manufacturing capacity, especially for sterile injectable lyophilized products, is a significant constraint and driver of cost and supply reliability.
• Generic entry increases demand, potentially straining existing capacity and leading to higher manufacturing costs.

FAQs

1. What are the primary challenges in sourcing micafungin API? The primary challenges include the complex multi-step synthesis requiring specialized chemistry expertise, stringent GMP compliance, securing high-purity raw materials, controlling impurities to meet regulatory standards, and the limited number of qualified API manufacturers capable of producing this lipopeptide.

2. How do patent expirations for micafungin impact its supply chain? Patent expirations enable generic manufacturers to enter the market, which increases the overall demand for micafungin API and finished dosage forms. This can strain existing manufacturing capacity, potentially leading to longer lead times and increased costs for contract manufacturing services. It also necessitates navigating secondary patents and potential litigation.

3. What role do Contract Manufacturing Organizations (CMOs) play in the micafungin supply chain? CMOs are crucial for both API synthesis and finished dosage form manufacturing, particularly for generic companies that may not have extensive in-house capabilities. They provide specialized manufacturing expertise, sterile fill-and-finish capacity (including lyophilization), and help manage production volumes to meet market demand.

4. What are the most significant regulatory hurdles for micafungin suppliers? The most significant regulatory hurdles include adhering to current Good Manufacturing Practices (cGMP) for both API and finished products, rigorous impurity profiling and control as per ICH guidelines, maintaining Drug Master Files (DMFs) or obtaining Certificates of Suitability (CEPs) for API, and complying with serialization and track-and-trace requirements for supply chain security.

5. How does the geographical concentration of pharmaceutical manufacturing affect micafungin supply stability? Geographical concentration of API and FDF manufacturing, often in regions like India and China, introduces risks related to geopolitical instability, trade disputes, natural disasters, and logistical challenges. Disruptions in these key regions can have a significant impact on the global availability and cost of micafungin due to the extended supply chains involved.

Citations

[1] United States Patent and Trademark Office. (n.d.). U.S. Patent 5,352,787. Retrieved from USPTO Patent Public Search. [2] European Patent Office. (n.d.). EP 0573814 B1. Retrieved from Espacenet. [3] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from FDA website. [4] European Medicines Agency. (n.d.). EudraLex Volume 4 - Good manufacturing practice. Retrieved from EMA website. [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from ICH website.